Survey on the occurrence of heart failure after administration of TARLIGE -MID-NET Cohort Study

Matsuoka for Yomei0 sites24,000 target enrollmentJuly 2, 2022

Overview

No summary available.

Registry

who.int

Start Date

July 2, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

Matsuoka for Yomei

•Patients who meet all of the following criteria will be enrolled.
•1\) During the enrollment period (April 15, 2019 to June 30, 2025\), there is a prescription date for either mirogabalin, an extract from inflammatory rabbit skin inoculated by vaccinia virus, or pregabalin (hereinafter referred to as the Target Drug).
•Hereinafter, the earliest prescription date among all prescription dates for the target drug during the enrollment period will be defined as the first prescription date.
•2\) The date of the earliest medical record after the start date of the data period is at least 366 days prior to the date of the first prescription during the enrollment period.

•Exclude patients who meet any of the following criteria:
•1\) There is a prescription date for the target drug between 365 days prior to the first prescription date and the day prior to the first prescription date.
•2\) There are several prescribing dates for the target drug on the first prescription date.
•3\) Between 180 days prior to the first prescription day and the first prescription day, the BNP value at the measurement day closest to the first prescription day is \>100 pg/ml.
•4\) There is a date of diagnosis of heart failure before the first prescription date.
•5\) Between 1826 days prior to the first prescription date and the first prescription date, there is a prescription date for chemotherapy or radiation therapy for malignancies.
•6\) There is a date of dialysis prior to the first prescription date.